Oncology Corporate Profile
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|somatuline||somatostatin analog inhibitor||Neuroendocrine tumor||III|
|decapeptyl (triptorelin pamoate)||decapeptide analogue||Prostate cancer||III|
|tasquinimod||oral quinolone-3-carboxamid||Prostate cancer||II||Active Biotech|
|tasquinimod||oral quinolone-3-carboxamid||Various cancer types||II|
View additional information on product candidates here »